公司金融 · 2025-12-26

Drivers of Revenue Growth in DCF Models: Assumptions on Market Share and Industry Expansion

The SFC’s 2024-25 enforcement priorities, which now place “prospectus disclosure quality” alongside “financial crime” as a core supervisory focus, have fundamentally changed the burden of proof for sponsors. In a December 2024 circular, the SFC explicitly warned that revenue forecasts in IPO prospectuses must be “demonstrably supportable by objective market data” – a standard that effectively bans the use of top-down “management guesstimates” that have historically padded DCF valuations. This regulatory shift arrives as Hong Kong’s Main Board IPO pipeline shows 78 active filers as of Q1 2025, according to HKEX data, each requiring a defensible revenue growth trajectory. For CFOs and financial advisors, the implication is clear: the old art of building a DCF on a 15% CAGR assumption backed by a single industry report is no longer sufficient. The SFC now expects a granular, bottom-up model that decomposes revenue growth into two primary levers – market share capture and industry expansion – each supported by verifiable, jurisdiction-specific data. This article examines the mechanics of these two drivers, the common errors that trigger SFC queries, and the data sources that pass regulatory scrutiny.

The market share assumption is the most frequently challenged revenue driver in SFC prospectus reviews. A 2023 study by the University of Hong Kong’s Faculty of Law found that 62% of rejected IPO applications cited “unsubstantiated market share projections” as a contributing factor. The core problem is methodological: most sponsors use a top-down approach that multiplies a total addressable market (TAM) by a target market share, without validating the feasibility of achieving that share within the forecast period.

The TAM Trap: Why Aggregate Market Data Fails Regulatory Scrutiny

The SFC’s December 2024 circular on “Revenue Forecasts in Listing Documents” (SFC, 2024) explicitly warns against using “aggregate industry-level data that does not reflect the issuer’s specific competitive position.” The trap is that TAM figures from third-party reports (e.g., Frost & Sullivan, IDC) are often calculated using broad assumptions about product categories, geographic boundaries, and customer segments that do not match the issuer’s actual addressable market.

For example, a Chinese biotech company targeting the “global oncology drug market” – valued at HKD 1.8 trillion in 2024 according to IQVIA data – would be committing a fundamental error if it assumed a 1% market share within five years. The SFC’s expectation is that the issuer must define a “serviceable obtainable market” (SOM), not a TAM. This SOM must be segmented by: (1) specific therapeutic area (e.g., non-small cell lung cancer, not “oncology”); (2) regulatory approval timeline (e.g., only markets where NMPA or FDA approval is expected within the forecast period); and (3) reimbursement coverage (e.g., only provinces where the drug is on the NRDL).

The mathematics of this segmentation are punishing. A TAM of HKD 1.8 trillion becomes a SOM of perhaps HKD 12 billion after applying a 0.7% incidence rate for the specific cancer type, a 40% addressable patient share after accounting for competing therapies, and a 25% reimbursement penetration rate. The implied market share of 0.07% is a far more defensible starting point than the original 1%.

The Growth Trajectory: S-Curves vs. Linear Projections

Once the SOM is established, the market share growth trajectory must reflect real-world adoption patterns. The SFC’s 2023 “Guidance on Financial Projections in Listing Documents” (SFC, 2023) states that “projections should be consistent with the historical adoption patterns of comparable products in the same market.” This effectively mandates an S-curve model for most product-based revenue forecasts.

An S-curve assumption – where market share grows slowly in the first 12-18 months post-launch (due to physician education, formulary listing, and reimbursement approvals), accelerates during years 2-4 (as clinical data accumulates and word-of-mouth spreads), and then plateaus at a natural ceiling – is the only trajectory that passes regulatory scrutiny. A linear projection, where market share increases by 0.5 percentage points per annum from year one, is statistically indefensible.

The data to support an S-curve must come from comparable product launches. For a Hong Kong-listed medical device company, the sponsor should cite the adoption curve of a similar device approved by the FDA in the same therapeutic category. The “comparable” must match on at least three dimensions: (1) regulatory pathway (e.g., PMA vs. 510(k)); (2) reimbursement status (e.g., NTAP vs. DRG); and (3) competitive intensity (e.g., number of alternative devices in the market at launch). A 2024 analysis by the Hong Kong Medical Device Association found that only 12% of IPO medical device projections met this standard.

The most common error in market share assumptions is the assumption of static competition. A DCF model that projects a company’s market share increasing from 5% to 15% over five years implicitly assumes that competitors’ shares decline or that the market expands to accommodate the entrant. Neither assumption is automatically valid.

The SFC’s 2024 circular requires that “any assumption of market share gain must be accompanied by a competitor-by-competitor analysis showing how the issuer will win share.” This analysis must identify: (1) the specific competitors whose share will decline (e.g., “We expect to take share from Company X, which holds 22% of the market but has a patent expiry in 2026”); (2) the switching costs for customers (e.g., “Our product is a direct replacement with no retraining required”); and (3) the pricing response (e.g., “We expect a 15% price decline in the first year as competitors react, which is already reflected in our ASP assumptions”).

Without this competitor analysis, the market share assumption is a “management guesstimate” that the SFC will flag. The practical solution is to build a market share model that includes a “competitive reaction function” – a mathematical representation of how each major competitor is expected to respond to the issuer’s entry, including price cuts, marketing spend increases, and product improvements.

The Industry Expansion Assumption: Forecasting the Market, Not the Company

The second revenue growth driver – industry expansion – is often treated as a residual variable in DCF models. This is a mistake. The SFC’s 2023 guidance explicitly states that “the industry growth rate must be supported by independent, verifiable data sources and must be consistent with the issuer’s specific market segment.” The error is using a high-level industry CAGR (e.g., “global healthcare spending grows at 5% per annum”) and applying it to the issuer’s revenue without adjusting for the issuer’s specific segment dynamics.

The Segment Granularity Problem: Why “Healthcare” is Not a Forecast

The Hong Kong Stock Exchange’s Listing Decision HKEX-LD144-2024 (HKEX, 2024) rejected a biotech prospectus because the issuer used a “global healthcare market CAGR of 6.2%” to support its revenue forecast. The HKEX noted that the issuer’s product – a diagnostic test for a rare genetic disorder – operated in a market segment that was growing at 18% per annum, not 6.2%. The error was not the direction of the bias but the lack of segment specificity.

The correct approach is to decompose the industry into three layers: (1) the macroeconomic layer (e.g., GDP growth, healthcare spending as a % of GDP); (2) the disease-specific layer (e.g., incidence rate trends, diagnostic adoption rates); and (3) the technology-specific layer (e.g., penetration of liquid biopsy vs. tissue biopsy). Each layer must be supported by a separate data source.

For a Hong Kong-listed diagnostics company, the forecast would look like this:

Layer 1: Hong Kong healthcare spending grows at 4.5% per annum (source: Hong Kong Census and Statistics Department, 2024).
Layer 2: Cancer screening rates in Hong Kong increase from 22% to 35% over five years (source: Hong Kong Cancer Registry, 2023).
Layer 3: Liquid biopsy adoption as a share of all cancer diagnostics grows from 8% to 18% (source: Frost & Sullivan, 2024, with the specific report title and page number cited).

The product of these three layers – 4.5% × (35%/22%)^(1/5) × (18%/8%)^(1/5) – yields a segment-specific CAGR of approximately 16.3%, not the 6.2% used in the rejected prospectus. The HKEX’s expectation is that the sponsor can produce this calculation with each input sourced from a verifiable, independent report.

The Regulatory Tailwind Assumption: When Policy Changes the Base Rate

Industry expansion assumptions that rely on regulatory changes (e.g., inclusion in the National Reimbursement Drug List, NRDL) require special treatment. The SFC’s 2023 guidance states that “any revenue forecast that depends on a regulatory approval or policy change must include a probability-weighted scenario analysis.”

For a Mainland Chinese pharmaceutical company listing in Hong Kong, the assumption that NRDL inclusion will increase revenue by 30% in year two must be probability-weighted. The probability of NRDL inclusion for a given drug is not a single number; it depends on: (1) the drug’s clinical efficacy relative to existing NRDL-listed drugs; (2) the price discount the company is willing to accept (typically 40-60% for oncology drugs); and (3) the timing of the next NRDL negotiation cycle.

A defensible model would assign a 40% probability to NRDL inclusion in year two (with a 30% revenue uplift), a 30% probability to inclusion in year three (with a 25% uplift due to market maturation), and a 30% probability to no inclusion within the forecast period (with revenue growing only at the underlying segment CAGR). The expected value of the revenue forecast is then the probability-weighted average of these scenarios. The SFC expects this calculation to be disclosed in the prospectus, not hidden in the sponsor’s working papers.

The Geographic Expansion Assumption: Cross-Border Data Consistency

For Hong Kong-listed companies with cross-border operations, the industry expansion assumption must be consistent across jurisdictions. A common error is to assume that a company’s revenue in China will grow at the China healthcare CAGR (6.5%) while its revenue in Southeast Asia grows at the global healthcare CAGR (4.2%). This is inconsistent if the company’s Southeast Asian operations are in markets like Vietnam (healthcare spending growing at 11.3% per annum, according to Vietnam Ministry of Health, 2024) or Indonesia (9.8% per annum, according to Indonesia Ministry of Health, 2023).

The SFC’s 2024 circular requires that “geographic revenue projections must be supported by country-specific data from the relevant national statistical authorities or recognized international organizations.” The practical implication is that a sponsor cannot use a single “emerging markets healthcare CAGR” for all non-China operations. Each country must have its own forecast, supported by a separate data source.

The most sophisticated error in DCF revenue forecasting is the failure to model the interaction between market share growth and industry expansion. A company that assumes it will gain market share while the industry expands at 10% per annum is implicitly assuming that its revenue will grow faster than 10% per annum – but the model rarely checks whether this combined growth rate is physically achievable given the company’s capacity constraints.

The Capacity Constraint: Why Revenue Growth Cannot Exceed Operational Reality

HKEX Listing Rule 11.06 requires that “the directors of the issuer must satisfy themselves that the projections are achievable within the issuer’s existing or planned resources.” This is a binding legal requirement, not a guidance note. If a company projects revenue growing at 25% per annum for five years, the sponsor must demonstrate that the company has the production capacity, sales force, and working capital to support that growth.

A practical test is the “capacity-to-revenue ratio.” If a manufacturing company’s current factory operates at 80% utilization and produces HKD 500 million in revenue, a projection of HKD 1.5 billion in revenue by year five implies either a 300% increase in capacity (requiring a new factory, which must be financed and built) or a 300% increase in utilization (which is physically impossible). The SFC expects the model to show the capital expenditure required to support the revenue growth, including the timing of the capex and the financing structure (debt vs. equity).

A market share gain assumption that does not account for price erosion is a red flag. The SFC’s 2023 guidance notes that “any assumption of market share gain should be accompanied by an analysis of the pricing dynamics in the market.” In practice, gaining market share typically requires price reductions, especially in competitive markets.

For a Hong Kong-listed consumer goods company, a model that assumes a 2% market share gain per annum while maintaining a 5% ASP increase per annum is internally inconsistent. The correct approach is to model a price-volume tradeoff curve, where the price elasticity of demand determines the relationship. If the price elasticity is -1.5 (a 1% price reduction leads to a 1.5% volume increase), then a 2% market share gain would require a 1.33% price reduction, not a 5% increase. The model must show both the volume gain and the price decline, with the net effect on revenue being the product of the two.

The Base-Year Effect: Why the First Year Matters Most

A common error in DCF models is the assumption that the base year (Year 0) is representative of the company’s long-term growth trajectory. This is rarely true for IPO-stage companies, which often have a “hockey stick” revenue pattern driven by a single large contract or a product launch.

The SFC’s 2024 circular requires that “the base year revenue must be adjusted for any non-recurring items, and the growth rate must be calculated from a normalized base.” For a company that had HKD 100 million in revenue in Year 0 but HKD 50 million in each of the prior two years, the base year is not representative. The sponsor must normalize the base year by using a three-year average (HKD 67 million) or by excluding the non-recurring contract.

The impact on the DCF valuation is material. A 20% CAGR from a normalized base of HKD 67 million yields HKD 167 million in Year 5 revenue. A 20% CAGR from the unadjusted base of HKD 100 million yields HKD 249 million – a 49% difference. The SFC expects the sponsor to disclose the normalization methodology and to show the sensitivity of the valuation to the base-year assumption.

Actionable Takeaways for CFOs and Sponsors

Decompose revenue growth into market share and industry expansion components, each supported by a separate, verifiable data source. The SFC’s December 2024 circular explicitly bans “management guesstimates” that combine both drivers into a single CAGR figure.
Define the serviceable obtainable market (SOM), not the total addressable market (TAM), and segment it by therapeutic area, regulatory timeline, and reimbursement coverage. A TAM-to-SOM conversion ratio below 5% is typical for specialty products and should be disclosed in the prospectus.
Use an S-curve adoption model for market share growth, supported by comparable product launch data that matches on regulatory pathway, reimbursement status, and competitive intensity. A linear market share projection will not pass SFC review.
Probability-weight any revenue forecast that depends on a regulatory approval or policy change, and disclose the probability assumptions and scenario outcomes in the prospectus. The SFC requires a minimum of three scenarios: base case, upside, and downside.
Model the interaction between market share gains and price erosion, and include a capacity constraint analysis that shows the capital expenditure required to support the projected revenue growth. The sponsor must demonstrate that the company’s resources are sufficient to achieve the forecast under HKEX Listing Rule 11.06.